Tonix Pharmaceuticals stock halted ahead of FDA approval news
Celldex Therapeutics , Inc. (NASDAQ:CLDX) stock has reached its 52-week low, trading at $14.57, with technical indicators suggesting oversold conditions. According to InvestingPro analysis, the company maintains a strong financial position with more cash than debt on its balance sheet, while analysts have set price targets ranging from $36 to $90. The biopharmaceutical company, known for its pioneering work in the development of immunotherapies for cancer and other diseases, has seen a significant downturn over the past year. The stock's current price level reflects a stark contrast to its performance over the last 12 months, with Celldex experiencing a decline of nearly 63%. This decline underscores the volatility and challenges faced by the biotech sector, as companies like Celldex continue to invest heavily in research and development amidst a landscape of regulatory hurdles and market uncertainty. For deeper insights into CLDX's valuation and growth prospects, access the comprehensive Pro Research Report available exclusively on InvestingPro, which covers 15+ additional key metrics and expert analysis.
In other recent news, Celldex Therapeutics has been the subject of attention from multiple analyst firms. Morgan Stanley (NYSE:MS) initiated coverage on Celldex with an Overweight rating and set a price target of $46.00. This decision was influenced by the promising results of their lead candidate, barzolvolimab, in Phase 2 studies for chronic urticaria. Despite concerns about side effects and competition, Morgan Stanley sees significant potential in Celldex's pipeline. Meanwhile, H.C. Wainwright maintained its Buy rating for Celldex and reaffirmed a higher price target of $80.00. This confidence was bolstered by Celldex's recent presentation at the AAAAI 2025, where new preclinical data on their bispecific antibody, CDX-622, showed promising results. The dual inhibition of inflammation mediators by CDX-622 has been well-tolerated, with initial Phase 1 study results expected later this year. Both firms highlight the potential impact of upcoming data releases on Celldex's performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.